Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Juvista for Improving Appearance of Existing Scars
NCT00821457Phase 2Withdrawn
- Sponsor
- Renovo
- Start
- Jan 2009
- Primary completion
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avotermin in Severe cutaneous adverse drug reactions (SCARs) (2 arms), sponsored by Renovo. Primary endpoint: Change in scar appearance assessed by colour analysis at 6 months. Planned start Jan 2009; status: withdrawn.
02
Drugs
avotermin
03
Conditions
Severe cutaneous adverse drug reactions (SCARs)
Beyond the preview
Go deeper on NCT00821457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00821457.